Quiz for Clinicians – GLP-1 Prescribing Considerations
Reviewed by: HU Medical Review Board | Last reviewed: September 2026 | Last updated: September 2026
Every prescription in this class lands on top of a medication list that was already there. These five questions cover the GLP-1 prescribing considerations that follow — what needs adjusting, what caps the dose, and what the evidence says when a patient asks to come off.
Clinical Challenge
An adult taking a sulfonylurea is starting incretin therapy for weight management. What do the labels in this class direct regarding the existing agent?
Clinical Challenge
A patient using a combined oral contraceptive is beginning a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. What contraceptive precaution applies, and for how long?
Clinical Challenge
A pharmacovigilance analysis of the FDA Adverse Event Reporting System compared compounded formulations of these agents with manufactured products. What did it find?
Clinical Challenge
A patient who has reached a stable weight plateau asks about reducing or stopping treatment. Which option best reflects current evidence on maintenance after incretin-induced weight reduction?
Clinical Challenge
A small-molecule oral GLP-1 receptor agonist is to be used alongside a strong cytochrome P450 3A4 (CYP3A4) inhibitor. What does that agent's labeling direct?